ABT vs JNJ: Which Stock is Better?
Side-by-side comparison of Abbott Laboratories and Johnson & Johnson in 2026
Comparison Updated:
ABT
Abbott Laboratories
$124.64
JNJ
Johnson & Johnson
$209.72
Key Metrics Comparison
| Metric | ABT | JNJ | Winner |
|---|---|---|---|
| Market Cap | $219.16B | $492.44B | JNJ |
| P/E Ratio | 15.82 | 19.77 | ABT |
| EPS (TTM) | $7.96 | $10.34 | JNJ |
| Revenue Growth | 0.1% | 0.1% | ABT |
| Gross Margin | 56.3% | 68.4% | JNJ |
Analyze ABT
Full quant analysis
Analyze JNJ
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is ABT or JNJ a better investment?
Comparing ABT and JNJ: Abbott Laboratories has a market cap of $219.16B while Johnson & Johnson has $492.44B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between ABT and JNJ?
ABT (Abbott Laboratories) and JNJ (Johnson & Johnson) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: ABT or JNJ?
Based on P/E ratios, ABT trades at a lower multiple (15.8x vs 19.8x).